Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04691817 2026-01-07

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Phase 1/2 Recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06016179 2025-05-22

RIOT2

Phase 1 Recruiting

12 enrolled

Thoracic

Pleural Effusion, Malignant

NCT05619744 2025-03-10

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Phase 1 Completed

41 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05769959 2024-07-09

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Phase 1 Terminated

3 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Clinical Trials

TCR1188-ABC Cells in KRAS-mutated Cancers

Morpheus Lung

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

RIOT2

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors